Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
73 hedge funds and large institutions have $121M invested in Sorrento Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 5 closing their positions.
540% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 5
213% more capital invested
Capital invested by funds: $38.6M → $121M (+$82.4M)
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
59% more funds holding
Funds holding: 46 → 73 (+27)
38% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.67M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.5M |
| 2 |
BlackRock
New York
|
+$8.67M |
| 3 |
Renaissance Technologies
New York
|
+$6.38M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.96M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$9.41M |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
-$1.27M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.15M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$448K |
| 5 |
JP Morgan Chase
New York
|
-$259K |
SRNE Hedge Fund Activity: Q1 2018 in Review
73 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2018, worth a combined $121M — up 213% from $38.6M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SRNE positions and 5 closed out — a net gain of 27 holders — while 25 added to existing stakes and 11 trimmed.
The largest buyer was State Street, adding an estimated $36.5M. The largest seller was Wildcat Capital Management, cutting an estimated $9.41M.
- 73 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2018, up from 46 in Q4 2017.
- Funds reported $121M of Sorrento Therapeutics, Inc. stock for Q1 2018, up 213% quarter-over-quarter.
- 32 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2018 and 5 closed out, a net change of +27 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2018 was State Street, an estimated $36.5M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2018 was Wildcat Capital Management, an estimated $9.41M sold.
Based on aggregated 13F filings for Q1 2018.